StockNews.AI
NCNA
StockNews.AI
3 days

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

1. NuCana initiates expansion study for NUC-7738 targeting resistant melanoma. 2. Positive initial data on NUC-7738 and NUC-3373 expected by late 2025. 3. Cash runway extended into 2029 following successful ATM capital raise. 4. Second quarter net loss reported at £24.1 million, up from £7 million last year.

Earnings
+6.43%Current Return
VS
-0.4%S&P 500
$3.1108/20 04:07 PM EDTEvent Start
$3.3108/21 09:16 PM EDTLatest Updated
14m saved
Insight
Article

FAQ

Why Bullish?

The encouraging clinical results and cash runway extension position NuCana favorably for growth, similar to companies like Immunomedics prior to their FDA approvals, which saw stock appreciation after positive trial results.

How important is it?

The article discusses crucial clinical milestones and financial positioning pertinent to NuCana's stock performance, impacting investor sentiment and market valuation significantly.

Why Long Term?

The anticipated positive data releases in late 2025 and regulatory advancements in 2026 will likely sustain investor interest and support stock performance over time.

Related Companies

IMMUNVSBMY
August 20, 2025 16:05 ET  | Source: NuCana plc First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Strategic Execution of ATM Offering Extends Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced financial results for the second quarter ended June 30, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines. “We are pleased to announce that the first patients have been dosed on the expansion of our ongoing Phase 1/2 NuTide:701 study in patients with PD-1 inhibitor-resistant melanoma,” said Andrew Kay, NuCana’s Executive Chairman. “Our lead program, NUC-7738 is a novel agent that profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. We remain encouraged by the clinical observations witnessed so far. We have observed a favorable safety profile, meaningful tumor volume reduction and prolonged progression free-survival in patients with PD-1 inhibitor refractory and resistant metastatic melanoma. The expansion study is expected to enroll an additional 28 patients, increasing the planned patient population treated in combination with pembrolizumab to 40 and further supporting our registrational path.” Mr. Kay continued, “Turning to our second program, NUC-3373 is a targeted thymidylate synthase inhibitor with immune modulating properties. We are encouraged by the data from the Phase 1b/2 NuTide:303 study, which is evaluating NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors, and NUC-3373 with docetaxel in patients with lung cancer. Notable tumor volume reductions and prolonged progression free survival have been observed in these patients so far. We look forward to announcing additional data from this study later this year.” Mr. Kay concluded, “Lastly, we strengthened our balance sheet with a financing in May and the strategic execution of an at-the-market (“ATM”) offering, extending our cash runway into 2029 and through key value-driving milestones. To date in 2025, these initiatives have raised gross proceeds of $38.4 million and with multiple data readouts ahead, we are well-positioned to deliver on our mission of improving treatment outcomes for patients with cancer.” Anticipated Milestones NUC-7738Announce initial data from the Phase 1/2 expansion study (NuTide:701) of NUC-7738 in combination with pembrolizumab in 2025;Obtain regulatory guidance from the U.S. Food and Drug Administration on pivotal study design for NUC-7738 in melanoma in 2026; andAnnounce final data from the Phase 1/2 expansion study (NuTide:701) of NUC-7738 in combination with pembrolizumab in 2026. NUC-3373Announce additional data from the Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with pembrolizumab in patients with solid tumors in 2025. Second Quarter 2025 Financial Highlights and Cash Position As of June 30, 2025, NuCana had cash and cash equivalents of £8.4 million compared to £4.0 million as of March 31, 2025 and £6.7 million at December 31, 2024. Subsequent to June 30, 2025, NuCana has raised, through the ATM offering, an additional £19.0 million in gross proceeds before expenses and commission. On July 21, 2025, having raised the full amount of capital required, NuCana announced it had successfully canceled all remaining Series A Warrants issued in the May 2025 financing, in exchange for payments of $3.6 million. This initiative fully eliminated all overhanging rights from the May 2025 financing. NuCana expects that its cash and cash equivalents as of June 30, 2025, together with amounts raised via the ATM offering, will be sufficient to fund its planned operations into 2029. NuCana continues to advance its clinical programs and reported a net loss of £24.1 million for the quarter ended June 30, 2025, which includes a loss on revaluation of the warrants issued in the May 2025 financing of £12.6 million, as compared to a net loss of £7.0 million for the quarter ended June 30, 2024. Basic and diluted loss per ordinary share was £0.00 for the quarter ended June 30, 2025, as compared to £0.12 per ordinary share for the comparable quarter ended June 30, 2024. About NuCana NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently being evaluated in a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. Forward-Looking StatementsThis press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of the Company. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including NUC-7738 and NUC-3373; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; and the sufficiency of the Company’s current cash and cash equivalents to fund its planned operations into 2029. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to raise additional capital sufficient to fund our planned operations and the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations. Unaudited Condensed Consolidated Statements of Operations   For the Three Months EndedJune 30, For the Six Months EndedJune 30,     2025 2024  2025 2024   (in thousands, except per share data)  £ £  £ £ Research and development expenses (7,104)(6,769) (8,829)(13,552)Administrative expenses (4,523)(1,509) (5,590)(3,090)Net foreign exchange (losses) gains (202)(74) (261)21 Operating loss (11,829)(8,352) (14,680)(16,621)Finance income 35 85  60 211 Finance expense (12,648)-  (12,648)- Loss before tax  (24,442)(8,267) (27,268)(16,410)Income tax credit 328 1,272  681 2,577 Loss for the period (24,114)(6,995) (26,587)(13,833)       Basic and diluted loss per ordinary share (0.00)(0.12) (0.01)(0.25) Unaudited Condensed Consolidated Statements of Financial Position As At   June 30,2025 December 31, 2024   (in thousands)  ££Assets   Non-current assets   Intangible assets 2,199  2,199 Property, plant and equipment 178  197 Deferred tax asset 112  113   2,489  2,509 Current assets   Prepayments, accrued income and other receivables 1,020  922 Current income tax receivable 4,266  4,594 Cash and cash equivalents 8,443  6,749   13,729  12,265 Total assets 16,218  14,774     Equity and liabilities   Capital and reserves   Share capital and share premium 171,673  151,827 Other reserves 86,407  78,421 Accumulated deficit (250,696) (224,294)Total equity attributable to equity holders of the Company 7,384  5,954     Non-current liabilities   Provisions 58  37 Lease liabilities 79  117   137  154 Current liabilities   Trade payables 1,098  2,705 Payroll taxes and social security 185  134 Accrued expenditure 4,735  5,714 Lease liabilities 75  73 Provisions -  40 Derivative financial instruments 2,604  -   8,697  8,666 Total liabilities 8,834  8,820 Total equity and liabilities 16,218  14,774      Unaudited Condensed Consolidated Statements of Cash Flows  For the Six Months EndedJune 30,         2025                  2024       (in thousands) ££Cash flows from operating activities  Loss for the period(26,587) (13,833)Adjustments for:  Income tax credit(681) (2,577)Amortization and depreciation136  272 Movement in provisions(40) - Finance income(60) (211)Finance expense12,648  - Interest expense on lease liabilities5  10 Share-based payments8,247  1,292 Net foreign exchange losses (gains)387  (112) (5,945) (15,159)Movements in working capital:  (Increase) decrease in prepayments, accrued income and other receivables(113) 625 (Decrease) increase in trade payables(1,607) 2,734 (Decrease) increase in payroll taxes, social security and accrued expenditure(929) 725 Movements in working capital(2,649) 4,084 Cash used in operations(8,594) (11,075)Net income tax received999  4,015 Net cash used in operating activities(7,595) (7,060)Cash flows from investing activities  Interest received57  218 Payments for property, plant and equipment-  (3)Payments for intangible assets(96) (176)Net cash (used in) from investing activities(39) 39 Cash flows from financing activities  Payments for lease liabilities(41) (127)Proceeds from exercise of share options1  3 Proceeds from issue of share capital1,222  1,492 Proceeds from exercise of warrants4,436  - Proceeds from issue of warrants4,439  - Share issue expenses(296) (45)Net cash from financing activities9,761  1,323 Net increase (decrease) in cash and cash equivalents2,127  (5,698)Cash and cash equivalents at beginning of period6,749  17,225 Effect of exchange rate changes on cash and cash equivalents(433) 112 Cash and cash equivalents at end of period8,443  11,639     For more information, please contact: NuCana plcAndrew KayExecutive Chairman+44 131-357-1111 info@nucana.com ICR HealthcareChris Brinzey+1 339-970-2843Chris.Brinzey@ICRHealthcare.com

Related News